Table 3.

Comparing the mean values of the five clinical parameters measured in this study 1 year before switching from reslizumab to mepolizumab to the mean values of the same parameters 6 months after switching.

Clinical Parameter Mepolizumab n = 8	1-year pre switch, Mean (SD)	6 months post switch, Mean (SD)	p-value
Hospital admissions(adjusted)	0.06 (0.18)	0	0.33
Exacerbations	0.44 (0.62)	0.13 (0.36)	0.24
Maintenance OCS dose (mg)	2.5 (5.18)	2.5 (5.18)	–
FEV1 (%), n = 7	78.8 (26.4)	67.6 (28.8)	0.02
ACQ score	1.6 (1.6)	1.5 (1.4)	0.43